Roche and the National Institute for Health and Care Excellence, which sets drug prices in Britain, are at a standoff over the price of Ocrevus, the pharma company’s MS drug. NICE has ruled the drug is too expensive for patients with relapsing-remitting MS. (Reuters)

The CEO of Memorial Sloan Kettering sent a memo to staff asking that they “do a better job” disclosing financial relationships with healthcare companies. (New York Times) The email was sent following a report by the The New York Times and ProPublica that MSK’s chief medical officer failed to disclose millions in consulting fees and equity in healthcare companies. (ProPublica)

The SEC has charged former Teva Pharmaceutical chairman Philip Frost with penny-stock fraud. The billionaire is accused of illegally promoting companies online in order to sell the shares at an inflated price. (STAT)

The FDA has rejected Amicus Therapeutics’ bid to seek a marketing application for its experimental drug for Pompe disease. The agency said it needs to see more clinical data first, pushing a filing until 2019. (STAT)

The family behind Purdue Pharma, the company responsible for producing and marketing OxyContin, owns a second opioid company, according to a report in The Financial Times. In addition to Purdue, the Sackler family owns the off-patent opioid manufacturer Rhodes Pharma. (Newsweek)